Life Expectancy in Pleural and Peritoneal Mesothelioma
Lung Cancer International · 2017
DOI: 10.1155/2017/2782590 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lung Cancer International, 2017. Verfasst von Robert Shavelle und 3 weiteren Autor:innen. Beteiligte Einrichtung: Life Expectancy Project, San Francisco, CA, USA. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Mesothelioma is a rare cancer with a historically dire prognosis. We sought to calculate life expectancies for patients with pleural or peritoneal mesothelioma, both at time of diagnosis and several years later, and to examine whether survival has improved in recent years.
Methods
Data on 10,258 pleural and 1,229 peritoneal patients from the SEER US national cancer database, 1973–2011, were analyzed using the Cox proportional hazards regression model.
Results
The major factors related to survival were age, sex, stage, grade, histology, and treatment. Survival improved only modestly over the study period: 0.5% per year for pleural and 2% for peritoneal.
Conclusions
Life expectancies were markedly reduced from normal, even amongst 5-year survivors with the most favorable characteristics and treatment options.
Autor:innen und Institutionen
- Life Expectancy Project, San Francisco, CA, USA.
ORCID-Profile: Robert Shavelle
Zitieren
APA
Shavelle, R., Vavra-Musser, K., Lee, J., & Brooks, J. (2017). Life Expectancy in Pleural and Peritoneal Mesothelioma. Lung Cancer International. https://doi.org/10.1155/2017/2782590
Vancouver
Shavelle R, Vavra-Musser K, Lee J, Brooks J. Life Expectancy in Pleural and Peritoneal Mesothelioma. Lung Cancer International. 2017. doi:10.1155/2017/2782590
BibTeX
@article{Shavelle2017,
author = {Shavelle, Robert and Vavra-Musser, Kate and Lee, Jessica and Brooks, Jordan},
title = {Life Expectancy in Pleural and Peritoneal Mesothelioma},
journal = {Lung Cancer International},
year = {2017},
doi = {10.1155/2017/2782590}
}
EUVIMED